阿尔茨海默病死亡率的变化从欧洲重要统计,2012-2020年
Marco Zuin1, Gloria Brombo1, Michele Polastri1
1Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
International journal of geriatric psychiatry
|March 2, 2024
概括
在欧盟27国,阿尔茨海默病的死亡率在过去十年中停滞不前,年龄调整后的死亡率停滞不前. 在欧盟成员国中,阿尔茨海默病 (AD) 死亡率的区域差异仍然很大.
科学领域:
- 神经学 神经学
- 公共卫生 公共卫生
- 老年学是一门学科.
背景情况:
- 关于欧盟 (EU-27) 中阿尔茨海默病 (AD) 死亡率趋势的数据有限.
- 了解这些趋势对于公共卫生规划和资源分配至关重要.
研究的目的:
- 分析2012年至2020年欧盟27个成员国阿尔茨海默病死亡率的性别和年龄特定趋势.
- 在欧盟27国内确定AD死亡率的区域差异.
主要方法:
- 利用欧洲统计局 (欧洲统计局) 关于死亡和人口的性别数据 (2012-2020年).
- 确定了使用ICD-10代码G30作为主要原因的AD死亡.
- 使用Joinpoint回归计算年度趋势,以确定年平均百分比变化 (AAPC).
主要成果:
- 在2012年至2020年期间,在欧盟27国发生了超过75万个因AD而导致的死亡.
- 阿尔茨海默病死亡的比例略有增加,而年龄调整后的死亡率显示停滞不前 (AAMR: -0.1%).
- 在整个研究期间,女性经历了更高的年龄调整后死亡率,区域差异显著.
结论:
- 在过去的十年里,阿尔茨海默病的年龄调整后死亡率在欧盟27国稳定.
- 西欧和东欧国家在阿尔茨海默病死亡率上存在显著差异,需要进一步调查.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.0K
相关概念视频
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Actuarial Approach
78
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
78
Variability: Analysis
143
Measures of variability are statistical metrics that reveal the dispersion pattern within a dataset. They are pivotal in biostatistics, providing insights into the heterogeneity within health and biological data. Variability signifies the degree to which data points diverge from one another, helping researchers understand the potential range of values and associated uncertainty within the data.
The range is a simple measure of variability, indicating the difference between the highest and...
The range is a simple measure of variability, indicating the difference between the highest and...
143
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Assumptions of Survival Analysis
126
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
126
Bias in Epidemiological Studies
265
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
265
